---
title: "AsymBio breaks ground on Fengxian R&D building, targets commissioning in H2 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293937005.md"
description: "AsymBio, a subsidiary of Asymchem Laboratories, has broken ground on a new eight-story R&D building at its Shanghai Fengxian site. Construction began in May 2026, with completion and commissioning targeted for the second half of 2027. The nearly 20,000 sq m facility aims to expand biologics development services, integrate early development with commercial manufacturing for antibodies and ADCs, and house the AccPCC platform to accelerate lead selection timelines."
datetime: "2026-07-27T13:03:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293937005.md)
  - [en](https://longbridge.com/en/news/293937005.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293937005.md)
generator: "portal-rs"
---

# AsymBio breaks ground on Fengxian R&D building, targets commissioning in H2 2027

-   AsymBio, a subsidiary of Asymchem Laboratories Tianjin Co. Ltd., broke ground on a new R&D building at its Shanghai Fengxian site. \* Construction started in May 2026; completion and commissioning targeted for 2H 2027. \* Eight-story facility planned with nearly 20,000 sq m of gross floor area to expand biologics development services. \* Site positioned to tighten integration between early development, scale-up, and commercial manufacturing for antibodies and ADCs. \* Building to house the AccPCC platform, aiming to shorten timelines from lead selection to preclinical candidate selection. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asymchem Laboratories Tianjin Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN12378) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [06821.HK](https://longbridge.com/en/quote/06821.HK.md)
- [002821.CN](https://longbridge.com/en/quote/002821.CN.md)

## Related News & Research

- [AsymBio to secure $184m to support growth in biologics manufacturing](https://longbridge.com/en/news/294940935.md)
- [Asymchem Laboratories announces extraordinary general meeting](https://longbridge.com/en/news/294528537.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million](https://longbridge.com/en/news/296542794.md)
- [BioArctic, Mesenkia partner to develop BrainTransporter-enabled antibody for glioblastoma](https://longbridge.com/en/news/296330014.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**